155 related articles for article (PubMed ID: 31464608)
1. The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma.
Benaniba L; Tessoulin B; Trudel S; Pellat-Deceunynck C; Amiot M; Minvielle S; Gourraud PA; de Visme S; Maisonneuve H; Lok A; Le Gouill S; Moreau P; Touzeau C
BMC Cancer; 2019 Aug; 19(1):855. PubMed ID: 31464608
[TBL] [Abstract][Full Text] [Related]
2. The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.
Hanf M; Chiron D; de Visme S; Touzeau C; Maisonneuve H; Jardel H; Pellat-Deceunynck C; Amiot M; le Gouill S
BMC Cancer; 2016 Oct; 16(1):802. PubMed ID: 27737650
[TBL] [Abstract][Full Text] [Related]
3. A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.
Efficace F; Boccadoro M; Palumbo A; Petrucci MT; Cottone F; Cannella L; Zamagni E; Niscola P; Kyriakou C; Caravita T; Offidani M; Mandelli F; Cavo M
Health Qual Life Outcomes; 2018 Jun; 16(1):127. PubMed ID: 29914509
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
5. Management of patients with difficult-to-treat multiple myeloma.
Richter J; Ramasamy K; Rasche L; Bladé J; Zweegman S; Davies F; Dimopoulos M
Future Oncol; 2021 Jun; 17(16):2089-2105. PubMed ID: 33706558
[TBL] [Abstract][Full Text] [Related]
6. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
7. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma.
Leng Y; Qiu L; Hou J; Zhao Y; Zhang X; Yang S; Xi H; Huang Z; Pan L; Chen W
Chin J Cancer; 2016 Sep; 35(1):86. PubMed ID: 27608772
[TBL] [Abstract][Full Text] [Related]
8. Advances in treatment for relapses and refractory multiple myeloma.
Richards T; Weber D
Med Oncol; 2010 Jun; 27 Suppl 1():S25-42. PubMed ID: 20213220
[TBL] [Abstract][Full Text] [Related]
9. New prognostic biomarkers in multiple myeloma.
Szudy-Szczyrek A; Szczyrek M; Soroka-Wojtaszko M; Hus M
Postepy Hig Med Dosw (Online); 2016 Jan; 70(0):811-9. PubMed ID: 27463592
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
Yang WC; Lin SF
Biomed Res Int; 2015; 2015():341430. PubMed ID: 26649299
[TBL] [Abstract][Full Text] [Related]
11. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
12. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
[TBL] [Abstract][Full Text] [Related]
13. [Daratumumab for multiple myeloma].
Croizier C; Bailly S
Bull Cancer; 2018 Nov; 105(11):985-991. PubMed ID: 30430991
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
15. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
[TBL] [Abstract][Full Text] [Related]
16. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Katodritou E; Terpos E; Symeonidis AS; Pouli A; Kelaidi C; Kyrtsonis MC; Kotsopoulou M; Delimpasi S; Christoforidou A; Giannakoulas N; Viniou NA; Stefanoudaki E; Hadjiaggelidou C; Christoulas D; Verrou E; Gastari V; Papadaki S; Polychronidou G; Papadopoulou A; Giannopoulou E; Kastritis E; Kouraklis A; Konstantinidou P; Anagnostopoulos A; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Aug; 89(8):803-8. PubMed ID: 24757085
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
18. Long-term stabilisation of myeloma with curcumin.
Zaidi A; Lai M; Cavenagh J
BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28413157
[TBL] [Abstract][Full Text] [Related]
19. [Expression and clinical significance of survivin in bone marrow cells of multiple myeloma patients].
Li J; Zhao Y; Zhang DB; Huang BH
Ai Zheng; 2005 Dec; 24(12):1522-6. PubMed ID: 16351806
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
